Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22288404 | 1.00 | POLB (0.55) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL683279 | 0.87 | BRD4 (0.47) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL684403 | 0.87 | BRD4 (0.47) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL684107 | 0.87 | BRD4 (0.47) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL8224207 | 0.85 | L3MBTL1 (0.43) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL2738632 | 0.85 | L3MBTL1 (0.43) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL2738475 | 0.85 | L3MBTL1 (0.43) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL679619 | 0.85 | AKT1 (0.43) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL680689 | 0.85 | AKT1 (0.43) | POLBKMT2AMEN1KDM4EMAPT | |
| SCHEMBL680930 | 0.85 | AKT1 (0.43) | POLBKMT2AMEN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115485276-B | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117964620-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113272304-B | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115485276-A | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-113272304-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020156437-A1 | AKT INHIBITOR | 南京正大天晴制药有限公司 | 2020-08-06 | — | — | WO | disclosed |
| EP-2850054-B1 | PROCESS FOR MAKING AMINO ACID COMPOUNDS | GENENTECH INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9790190-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790190-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170247337-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9416110-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2861582-B1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9315471-B2 | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | GENETECH, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315471-B2 | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | GENETECH, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9278917-B2 | Process for making amino acid compounds | GENENTECH, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150152067-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENENTECH, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150152067-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENENTECH, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150148559-A1 | PROCESS FOR MAKING AMINO ACID COMPOUNDS | GENENTECH, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152067-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | DPYD, DHPS, TYMP | POLB 142/4885KMT2A 1876/4885MEN1 1432/4885 |
| US-20150148559-A1 | PROCESS FOR MAKING AMINO ACID COMPOUNDS | MTOR, PIK3CA, AKT1S1 | POLB 639/4885KMT2A 993/4885MEN1 1419/4885 |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | PIK3CA, PIK3CD, PIK3CG | POLB 470/4885KMT2A 1856/4885MEN1 2738/4885 |
| US-20170247337-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | DPYD, DHPS, TYMP | POLB 142/4885KMT2A 1876/4885MEN1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.